Revenue growth trajectory and QTC expansion are positive, but cash burn and widening losses keep the stock binary on ZEVASKYN adoption. Watch for Q2 2026 patient treatment numbers and any ABO-701 IND timeline updates. The EPS beat vs consensus may provide a short-term lift, but sustained commercial execution is needed for a fundamental re-rating.
Price Chart
Executive Summary
Abeona reported Q1 2026 net product revenue of $8.7M from ZEVASKYN, up from $2.4M in Q4 2025, with three patients treated. Net loss widened to $(17.1)M ($(0.30)/share) from $(12.0)M a year ago, driven by SG&A ramp-up and a $7.0M licensing payment for ABO-701. Cash burn and lack of profitability keep the stock in speculative territory despite commercial progress.
Key Financial Metrics
Key Facts
- Q1 2026 net product revenue $8.7M (vs $2.4M Q4 2025, $0 in Q1 2025)
- Net loss $(17.1)M or $(0.30)/share vs $(12.0)M or $(0.24)/share in Q1 2025
- Cash, equivalents & short-term investments $168.3M as of March 31, 2026 (down from $191.4M Dec 31, 2025)
- Three patients treated with ZEVASKYN in Q1 2026; QTC network expanded to six sites
- In-licensed ABO-701 (PSMA-SIR-T) for prostate cancer; IND expected H2 2027
- Ophthalmology programs deprioritized
- EPS $(0.30) vs consensus $(0.39) — a 23% beat on a GAAP basis
Financial Impact
Q1 2026 product revenue $8.7M; net loss $(17.1)M; cash burn ~$23M in the quarter
Risk Factors
- Cash burn rate of ~$23M/quarter implies ~7 quarters of runway at current spend
- ZEVASKYN adoption still early — only 3 patients treated in Q1; revenue concentration risk
- ABO-701 is preclinical; IND not expected until H2 2027 — no near-term catalyst
- Accumulated deficit of $(759)M with no path to profitability visible
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293883 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $5.47 $5.57 | ▲ +1.83% | ▲ +1.01% | $5.03 (−8.14%) |
Aug 14, 2026 6w ago | Institutional Cluster | $5.94 $6.06 | ▲ +2.02% | ▲ +3.21% | $5.03 (−15.40%) |
Aug 13, 2026 7w ago | 8-K | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Aug 13, 2026 7w ago | Press Release | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Jul 9, 2026 12w ago | Insider Cluster | $6.98 $7.02 | ▲ +0.57% | ▲ +1.13% | $5.03 (−28.01%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▲ +1.24% | ▲ +3.47% | $5.03 (−11.06%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▼ −1.24% | ▼ −3.47% | $5.03 (+11.06%) |
Jun 12, 2026 16w ago | 8-K | $5.53 $5.77 | ▲ +4.34% | ▲ +3.67% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | 8-K | $5.53 $5.65 | ▲ +2.17% | ▲ +1.74% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | Insider Cluster | $5.36 $5.65 | ▼ −5.41% | ▼ −1.98% | $5.03 (+6.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access